<DOC>
	<DOCNO>NCT02410369</DOCNO>
	<brief_summary>In clinical study , investigator evaluate efficacy safety S-588410 patient underwent adjuvant chemotherapy complete resection non-small-cell lung cancer .</brief_summary>
	<brief_title>Study S-588410 After Adjuvant Chemotherapy Completely Resected Non-small- Cell Lung Cancer</brief_title>
	<detailed_description>In phase II trial , investigator evaluate efficacy safety S-588410 contain oncoantigens-derived HLA-A*2402-restricted epitope peptide patient HLA-A*2402 underwent adjuvant chemotherapy complete resection non-small-cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Patients receive platinumbased adjuvant chemotherapy complete resection lung cancer . 2 . Pathologically determine nonsmallcell lung cancer except large cell neuroendocrine carcinoma mixed type . 3 . Patients HLAA*24:02 . 4 . Neither recurrence metastasis nonsmallcell lung cancer demonstrate image test within 6 week prior registration . 5 . Possible receive S588410 within 12 week last adjuvant chemotherapy . 6 . ECOG performance status 0 1 within 2 week prior registration . 7 . Age 20 year time consent acquisition . 8 . The write informed consent provide patient . 1 . Other malignant disease require treatment , except cured cancer insitu . 2 . Concurrent treatment anticancer drug , steroid , immunosuppressive agent , radiotherapy , immunotherapy , hyperthermia , surgery . 3 . Active uncontrolled infectious disease . 4 . Severe hepatic dysfunction , kidney dysfunction , cardiac disease , pulmonary disease , hematological disorder , metabolic disease . 5 . Coronary artery stenting within 6 month prior registration . 6 . Autoimmune disease . 7 . HIV infection . 8 . Registration within 4 week last adjuvant chemotherapy . 9 . Laboratory value define protocol within 2 week prior registration . 10 . Residual uncontrolled adverse event adjuvant chemotherapy . 11 . Eosinophilia within 28 day prior registration . Past active eosinophilic pneumonia interstitial pneumonitis . 12 . Past history severe allergic reaction drug , vaccine biological agent . 13 . Female patient nursing pregnancy . 14 . Refusal pregnancy conception . 15 . Treated peptide vaccine S588410 . 16 . Treated another investigational drug within 28 day prior registration period 5 time drug halflife . 17 . Decision nonenrollment patient principal investigator physicianincharge view point patient 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>